Columbus Venture Partners
Also known as Columbus VP, Columbus Venture Partners, SGEIC, S.A.
Valencia life-sciences VC manager (SGEIC) founded 2016 by Damià Tormo and Javier García; Columbus Life Sciences funds split between therapies and industrial biotech.
- HEADQUARTERS
- Paterna (Valencia), Spain
- FOUNDED
- 2016
- AUM
- —
- OUTSIDE CAPITAL
- Yes
- TEAM LISTED
- 9 people
Focus
- STAGES
- Series ASeries BGrowth
- ASSET MIX
- Venture capitalDirect investments
- GEOGRAPHY
- SpainEuropeNorth America
Investment arms & vehicles
- Seda Capital Partners, SGEIC, S.A.Second management company of the group (same holding owner, chaired by Damià Tormo); manages Seda Blue Tech Fund FCR and the Columbus Innovation I and Columbus Special Situations SCRs
Overview
Columbus Venture Partners is a venture capital management company specialised in biotechnology, based in the Valencia technology park in Paterna and registered with the CNMV as an SGEIC. It was founded in 2016 by Damià Tormo and Javier García; it states it has completed four funds through which it has invested in 50 biotech companies. Its funds balance therapeutic programmes and industrial biotech infrastructure (e.g. gene-therapy manufacturer Viralgen, sold to Bayer in 2020). Fund sizes reported: Columbus Innvierte Life Science I (2016, €42M), Life Science II (2019, €74M), Life Sciences III (2021, €120M) and Life Sciences IV (2023, €150M); Columbus Innvierte Life Sciences Fund V received a CDTI commitment of up to €70M in 2026.
Investment thesis
Funds diversified roughly 50% in therapies and 50% in industrial development; originates its own companies and invests in European and US life-sciences companies, with exit routes designed before investing.
PORTFOLIO (12)
- ViralgenNOTABLEBiotech & Life Sciences · Acquired
- AskBioNOTABLEBiotech & Life Sciences · Acquired
- Sanifit TherapeuticsNOTABLEBiotech & Life Sciences · Acquired
- Aura BiosciencesNOTABLEBiotech & Life Sciences · IPO
- VivetBiotech & Life Sciences
- Minoryx TherapeuticsBiotech & Life Sciences
- Arthex BiotechBiotech & Life Sciences
- Highlight TherapeuticsBiotech & Life Sciences
- Integra TherapeuticsBiotech & Life Sciences
- QuibimHealthTech
- Syngoi TechnologiesBiotech & Life Sciences · Acquired
- CurapathBiotech & Life Sciences · Acquired
People
- Damià TormoGeneral Partner · source
- Javier GarcíaGeneral Partner · source
- Julen OyarzabalPartner · source
- Marc MarcoPartner · source
- Jose MesaPartner · source
- Robert ArmstrongPartner · source
- Eva RodrigoChief Financial Officer · source
- Cristo GordilloChief Legal Officer · source
- Ana TaberneroInvestor Relations · source
Links
Frequently asked questions
Columbus Venture Partners is a VC fund based in Paterna (Valencia), Spain, founded in 2016.
Yes. Columbus Venture Partners invests its own capital in private companies.
Columbus Venture Partners invests at Series A, Series B and Growth stages in Biotech & Life Sciences and HealthTech.
Key people at Columbus Venture Partners include Damià Tormo (General Partner), Javier García (General Partner), Julen Oyarzabal (Partner) and Marc Marco (Partner).
Columbus Venture Partners's investments include Viralgen, AskBio, Sanifit Therapeutics, Aura Biosciences, Vivet, Minoryx Therapeutics, Arthex Biotech and Highlight Therapeutics, among others.
The most recent publicly reported investment by Columbus Venture Partners is Visium (First institutional round (co-led with Concentric)), announced in May 2026.
Yes. Columbus Venture Partners manages capital from outside investors.